Cutaneous Squamous Cell CarcinomaPhase 2NCT06288191
Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma
A Phase 2 study testing Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination in people with Cutaneous Squamous Cell Carcinoma, run by Melanoma Institute Australia at 1 site in Australia.
Trial summary
The goal of this study is to test neoadjuvant therapy with the dual inhibition of Programmed cell death protein 1 (PD-1) and lymphocyte activation gene 3 (LAG-3) immune checkpoint pathways in a cohort of treatment-naïve, resectable stage II to IV cutaneous squamous cell carcinoma on the pathological response rate… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cutaneous Squamous Cell Carcinoma
- What is being tested?
- Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteAustralia
- Study dates
- 21 Jun 2024to Jul 2036
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- ≥ 18 years of age
- Written informed consent
- Histologically confirmed, resectable stage II to IV cutaneous squamous cell carcinoma defined as:
- Non-head and neck cuSCC:
- stage II (T2, N0, M0)
- stage III (T3, N0, M0; or T1-3, N1, M0)
Show all 19Show fewer
- stage IV (T1-3, N2 or N3, M0; or T4a or T4b, any N, M0)
- Cutaneous head and neck CC:
- stage II (T2, N0, M0)
- stage III (T3, N0, M0)
- stage IV (T4a or T4b, any N, M0)
- In-transit metastases (ITM) are permitted if they are completely resectable. ITM defined as skin or subcutaneous metastases that are > 20 mm from the primary lesion but not beyond the regional nodal basin.
- Measurable disease according to RECIST version 1.1 criteria (≥10 mm longest diameter for primary lesions and / or ≥10 mm in shortest diameter for lymph nodes as determined by CT imaging) within 2 weeks of the start of study treatment.
- Tumour amenable to a newly obtained core biopsy of a lesion which has not been previously irradiated. Archival tissue from a past primary or nodal cuSCC lesion (if applicable) or tissue taken for current diagnosis will also be collected.
- Previous radiotherapy permitted if performed at a prior site of disease not seen at baseline.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Documented adequate haematological, hepatic, renal, and thyroid function determined by blood pathology
- Anticipated life expectancy of > 12 months
- Women of childbearing potential must have a negative serum pregnancy test within 24 hours of the first dose of study treatment or within 72 hours if this is not feasible. Effective contraception should be used for the duration of study treatment and for 5 half-lives (or 5 months) after the last dose. Egg donation (ova, oocytes) should be avoided for the same period. There are no partner-pregnancy or sperm donation avoidance requirements for male patients.
Who cannot join
- Clinical or radiographic evidence of distant metastasis
- SCC of the eyelid, vulva, penis and perianus
- Any contraindication to the administration of nivolumab and / or relatlimab
- Prior anti-PD-1, CTLA-4 (Cytotoxic T-lymphocyte associated protein 4), PDL-1 (Programmed death-ligand 1) or LAG 3 (Lymphocyte-Activation Gene 3) antibody exposure, or an agent directed to another stimulatory or co-inhibitory T-cell receptor for any disease or any chemotherapy or experimental local or systemic drug treatment
- Active autoimmune disease or a requirement for chronic steroid therapy other than hormone replacement therapy
- The following are permitted:
Show all 43Show fewer
- Vitiligo
- Type I diabetes mellitus on stable insulin therapy
- Residual autoimmune hypothyroidism on stable hormone replacement
- Resolved childhood asthma or atopy
- Psoriasis not requiring systemic treatment
- Autoimmune conditions which are not expected to recur in the absence of an external trigger.
- Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in doses exceeding 10 mg daily of prednisone or equivalent) or any other form of immunosuppressive therapy within 14 days prior to the first dose of study treatment.
- The following are permitted:
- Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.)
- Inhaled or intranasal corticosteroids (with minimal systemic absorption) may be continued if patient is on a stable dose
- Non-absorbed intra-articular steroid injections.
- Known additional malignancies (unless adequately treated) active within the previous 3 years, except for locally curable cancers that have been apparently cured.
- The following malignancies, if undergone successful definitive resection or curative treatment, are permitted:
- Basal cell carcinoma of the skin
- Squamous cell carcinoma of the skin
- Carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ, but excluding carcinoma in situ of the bladder) that have undergone potentially curative therapy
- Prostatic intraepithelial neoplasia
- In situ melanoma
- Atypical melanocytic hyperplasia
- Multiple primary melanomas
- Other malignancies for which the patient has been disease free for 3 years, not requiring active anti-cancer therapy.
- Uncontrolled or significant cardiovascular disease including, but not limited to any of the following:
- Myocardial infarction (MI) or stroke/transient ischemic attack within the 6 months prior to consent
- Uncontrolled angina within the 3 months prior to consent
- Any history of clinically significant arrhythmias (such as poorly controlled atrial fibrillation, ventricular tachycardia, ventricular fibrillation, or torsades de pointes)
- QTc (corrected QT interval) prolongation > 480 ms
- History of other clinically significant cardiovascular disease (i.e. cardiomyopathy, congestive heart failure with New York Heart Association functional classification III-IV, pericarditis, significant pericardial effusion, significant coronary stent occlusion, poorly controlled venous thrombosis, etc)
- Cardiovascular disease-related requirement for daily supplemental oxygen
- History of 2 or more M.I.s OR 2 or more coronary revascularisation procedures (regardless of the number of stent placements during each procedure)
- Patients with history of myocarditis, regardless of aetiology.
- Troponin T (TnT) or I (TnI) >2 × institutional ULN (upper limit of normal). Participants with TnT or TnI levels between >1 to 2 × ULN will be permitted if repeat levels within 24 hours are ≤1 ULN. If TnT or TnI levels are between >1 to 2 × ULN within 24 hours, the participant may undergo a cardiac consultation and be considered for treatment, following cardiologist recommendation. When repeat levels within 24 hours are not available, a repeat test should be conducted as soon as possible. If TnT or TnI repeat levels beyond 24 hours are <2 × ULN, the participant may undergo a cardiac consultation and be considered for treatment, following cardiologist recommendation. Notification of the decision to enrol the participant following cardiologist recommendation must be made to the Lead Investigator.
- Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis or current interstitial lung disease.
- Has an active infection requiring systemic therapy.
- Has a known history of Human Immunodeficiency Virus (HIV). Note: no testing for HIV is required unless mandated by local health authority.
- Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive) or known active Hepatitis C virus (defined as HCV RNA [qualitative] is detected) infection. Note: no testing for Hepatitis B and Hepatitis C is required unless mandated by local health authority.
- Pregnant or breast-feeding females
- Concurrent medical or social conditions that may prevent the patient from attending assessments per schedule.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Australia1 site, 1 recruiting
- Recruiting
Melanoma Institute Australia
Wollstonecraft, New South Wales, 2065
Monica Osorio Clinical Trials Operations Manager, +612 2 9911 7296, Monica.Osorio@melanoma.org.au
About this study
Official title: A Phase 2, Open Label, Single Arm, Clinical Trial of Neoadjuvant Nivolumab and Relatlimab in Stage II To IV (M0) Resectable Cutaneous Squamous Cell Carcinoma
The goal of this study is to test neoadjuvant therapy with the dual inhibition of Programmed cell death protein 1 (PD-1) and lymphocyte activation gene 3 (LAG-3) immune checkpoint pathways in a cohort of treatment-naïve, resectable stage II to IV cutaneous squamous cell carcinoma on the pathological response rate (pCR) and recurrence-free survival.
Read the detailed description
This is a phase 2, open label, single cohort, single centre, clinical trial of neoadjuvant immunotherapy with dual inhibition of PD-1 and LAG-3 immune checkpoint pathways. The hypothesis is that neoadjuvant therapy produces a higher pathological response rate (pCR) and a longer recurrence-free survival in a cohort of treatment-naïve patients with resectable stage II to IV (M0) cutaneous squamous cell carcinoma compared to neoadjuvant cemiplimab monotherapy in Checkmate 358 (n=123, NCT04154943 , historical control).
- Conditions
- Cutaneous Squamous Cell Carcinoma
- Being tested
- Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination
- Keywords
- neoadjuvant, immunotherapy, pathological response
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combinationDrug
Also called Opdualag
Dual inhibition of the distinct LAG3 and PD-1 checkpoint pathways
| Study group | Role | What they receive |
|---|---|---|
| Neoadjuvant Treatment | Experimental | Nivolumab and relatlimab will be administered in a fixed dose combination (FDC). The dose and dosing regimen for this study is nivolumab 480 mg and relatlimab 160 mg - 2 vials per infusion. All patients are scheduled to receive two doses of nivolumab and relatlimab FDC prior to surgery on days 1 and 29. Patients without a complete pathological response to neoadjuvant therapy may receive standard of care radiotherapy per multidisciplinary team meeting discussion. Receives: Drug: Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pathological complete response rate
Proportion of patients with a pathological complete response, as determined on the week 6 surgical specimen using the guidelines published by the International Neoadjuvant Melanoma Consortium: Complete pathological response (pCR) = 0% viable tumour cells in the surgical specimen
Measured: Week 6
Secondary outcomes (12)
Pathological near pathological response (near pCR), partial response (pPR) and pathological non-response (pNR) rate
Proportion of patients with each non-pCR response category, as determined on the week 6 surgical specimen using the guidelines published by the International Neoadjuvant Melanoma Consortium (INMC):
- Major pathological response (pCR + near-pCR),
- Near complete pathological response - (near pCR) - >0% - ≤10% viable tumour
- Partial pathological response (pPR) - >10 - ≤50% viable tumour
- Non pathological response (pNR) - >50% viable tumour
Measured: Week 6
Toxicity and tolerability of neoadjuvant immunotherapy and surgery
The proportion of patients with adverse events (AE) per Common Terminology Criteria for Adverse Events (CTCAE), from initiation of study treatment until at least 135 days after the end of treatment. Outcome measures include the proportion of patients with each of the following measures:
- An AE by CTCAE term / grade
- AEs attributable to neoadjuvant treatment
- Grade 3/4/5 AEs by AE term
- The duration of events reported in (a)
- Delayed study treatment and/or delay surgery due to an AE
- A requirement to discontinue study treatment early due to an AE
- Oral or parenteral steroid treatment for immune-related adverse events.
- Post-operative complications (e.g. seroma formation, wound infection or lymphoedema) and duration of events.
- Post-operative complications at 3, 12 and 48 weeks using the Clavien-Dindo Classification.
- Surgeon's assessment of 'operability' and morbidity from baseline and at surgery per INMC questionnaires.
Measured: Week 48
Objective response rate to neoadjuvant therapy
The proportion of patients within each response category, as assessed using RECIST version 1.1, comparing week 6 to baseline CT and MRI.
Objective response rate= CR and PR
Measured: Week 6
Metabolic response rate to neoadjuvant immunotherapy
The proportion of patients within each response category, as assessed using the Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST) and the standardised uptake value (SUV) comparing week 6 to baseline positron emission tomography (PET) scan.
Metabolic response rate = Complete metabolic response (CMR) and partial metabolic response (PMR).
Measured: Week 6
Recurrence-free survival
The proportion of patients alive and disease free from the time of surgery
Measured: 10 years
Disease progression rate
The proportion of patients alive and with RECIST-defined progression of disease from the date of consent to the first radiographical evidence of local, regional or distant progression.
Disease progression which leads to unresectable cutaneous squamous cell carcinoma (cuSCC)
Measured: Week 6
Event-free survival rate
Proportion of patients with EFS defined as the earliest of any of the following events:
- Time from 1st dose study treatment to disease progression (unresectable stage III or stage IV disease),
- Time of surgery to recurrence of cuSCC (local, regional or distant)
- Treatment related death
- Disease related death
Measured: 10 years
Overall survival
The proportion of patients alive at years 1, 2, 5 and 10, and to actual date of death (in months), from the first dose of study treatment.
Measured: 10 years
Patient reported quality of life (QLQ-C30)
The published scoring for: The European Organization for the Research and Treatment of Cancer Quality of Life of Cancer Patients Questionnaire (QLQ-C30). A 30 item instrument where a higher score represents a higher ("better") level of functioning, or a higher ("worse") level of symptoms.
Changes in patient rated quality of life (QOL) scores using QLQ-C30 are recorded at baseline (within 7 days of first dose of study treatment) and at 6 -12 weekly intervals until the end of year 1 will be measured.
The correlation of the QLQ-C30 scores with adverse events will be measured.
Measured: 1 year
Patient reported quality of life (EQ-5L-5D)
The published scoring for: The European Quality of Life (EQ-5L-5D).
Each dimension has 5 levels: no problems, some problems, extreme problems.
The EQ visual analogue scale (VAS records) the respondent's self-rated health on a vertical, visual analogue scale where the endpoints are labelled 'Best imaginable, health state' and 'Worst imaginable health state'.
Changes in patient rated quality of life (EQ-5D-5L) scores recorded at baseline (within 7 days of first dose of study treatment) and at 6 -12 weekly intervals until the end of year 1 will be measured.
The correlation of the EQ-5L-5D scores with adverse events will be measured.
Measured: 1 year
Study treatment completion rate and the causes of any missed treatments
Proportion of patients receiving full neoadjuvant drug treatment per schedule and number of treatments missed.
Proportion of patients undergoing planned surgery at week 6. Reasons for incomplete study treatment e.g. adverse event, withdrawn consent, disease progression, patient lost to follow-up.
Measured: Week 8
De-escalation of adjuvant radiotherapy.
Proportion of patients where adjuvant radiotherapy was planned at baseline but who did not need radiotherapy as a result of pathological response and pathologically clear surgical margins.
Measured: Week 8
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Mar 2024
- Study start21 Jun 2024
- Primary completionSep 2026 (estimated)
- Study completionJul 2036 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cutaneous Squamous Cell CarcinomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Open label, single arm, single centre, clinical trial
- Masking
- None (open label)
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Melanoma Institute Australia
- Sponsor type
- University, hospital or other
- Collaborators
- Bristol-Myers Squibb
- Responsible party
- Sponsor
- Investigators
- Ines Da Silva, Principal investigator, Melanoma Instiute Australia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06288191
- Sponsor's protocol ID
- MIA2023/490
- Other IDs
- CA224-1065
- Status last verified
- Jul 2026
- First submitted
- 4 Feb 2024
- Last updated
- 8 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 2, Open Label, Single Arm, Clinical Trial of Neoadjuvant Nivolumab and Relatlimab in Stage II To IV (M0) Resectable Cutaneous Squamous Cell Carcinoma
- ClinicalTrials.gov ID
- NCT06288191
- Acronym / sponsor ID
- MIA2023/490
- Conditions
- Cutaneous Squamous Cell Carcinoma
- Keywords
- neoadjuvant, immunotherapy, pathological response
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- Melanoma Institute AustraliaUniversity, hospital or other
- Collaborators
- Bristol-Myers Squibb
- Study start
- 21 Jun 2024 (actual)
- Primary completion
- Sep 2026 (estimated)
- Study completion
- Jul 2036 (estimated)
- First posted
- 1 Mar 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this study is to test neoadjuvant therapy with the dual inhibition of Programmed cell death protein 1 (PD-1) and lymphocyte activation gene 3 (LAG-3) immune checkpoint pathways in a cohort of treatment-naïve, resectable stage II to IV cutaneous squamous cell carcinoma on the pathological response rate (pCR) and recurrence-free survival.
Detailed description
This is a phase 2, open label, single cohort, single centre, clinical trial of neoadjuvant immunotherapy with dual inhibition of PD-1 and LAG-3 immune checkpoint pathways. The hypothesis is that neoadjuvant therapy produces a higher pathological response rate (pCR) and a longer recurrence-free survival in a cohort of treatment-naïve patients with resectable stage II to IV (M0) cutaneous squamous cell carcinoma compared to neoadjuvant cemiplimab monotherapy in Checkmate 358 (n=123, NCT04154943 , historical control).
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Open label, single arm, single centre, clinical trial
| Arm | Type | Receives |
|---|---|---|
| Neoadjuvant Treatment | Experimental | Drug: Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combinationNivolumab and relatlimab will be administered in a fixed dose combination (FDC). The dose and dosing regimen for this study is nivolumab 480 mg and relatlimab 160 mg - 2 vials per infusion. All patients are scheduled to receive two doses of nivolumab and relatlimab FDC prior to surgery on days 1 and 29. Patients without a complete pathological response to neoadjuvant therapy may receive standard of care radiotherapy per multidisciplinary team meeting discussion. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (19 listed)
- ≥ 18 years of age
- Written informed consent
- Histologically confirmed, resectable stage II to IV cutaneous squamous cell carcinoma defined as:
- In-transit metastases (ITM) are permitted if they are completely resectable. ITM defined as skin or subcutaneous metastases that are > 20 mm from the primary lesion but not beyond the regional nodal basin.
- Measurable disease according to RECIST version 1.1 criteria (≥10 mm longest diameter for primary lesions and / or ≥10 mm in shortest diameter for lymph nodes as determined by CT imaging) within 2 weeks of the start of study treatment.
Key exclusion criteria (43 listed)
- Clinical or radiographic evidence of distant metastasis
- SCC of the eyelid, vulva, penis and perianus
- Any contraindication to the administration of nivolumab and / or relatlimab
- Prior anti-PD-1, CTLA-4 (Cytotoxic T-lymphocyte associated protein 4), PDL-1 (Programmed death-ligand 1) or LAG 3 (Lymphocyte-Activation Gene 3) antibody exposure, or an agent directed to another stimulatory or co-inhibitory T-cell receptor for any disease or any chemotherapy or experimental local or systemic drug treatment
- Active autoimmune disease or a requirement for chronic steroid therapy other than hormone replacement therapy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combinationAlso: OpdualagDual inhibition of the distinct LAG3 and PD-1 checkpoint pathways | Drug | Neoadjuvant Treatment |
Primary outcome
Pathological complete response rate
Time frame: Week 6
Proportion of patients with a pathological complete response, as determined on the week 6 surgical specimen using the guidelines published by the International Neoadjuvant Melanoma Consortium: Complete pathological response (pCR) = 0% viable tumour cells in the surgical specimen
12 secondary outcomes
Pathological near pathological response (near pCR), partial response (pPR) and pathological non-response (pNR) rate
Time frame: Week 6
Toxicity and tolerability of neoadjuvant immunotherapy and surgery
Time frame: Week 48
Objective response rate to neoadjuvant therapy
Time frame: Week 6
Metabolic response rate to neoadjuvant immunotherapy
Time frame: Week 6
Recurrence-free survival
Time frame: 10 years
Disease progression rate
Time frame: Week 6
Event-free survival rate
Time frame: 10 years
Overall survival
Time frame: 10 years
Patient reported quality of life (QLQ-C30)
Time frame: 1 year
Patient reported quality of life (EQ-5L-5D)
Time frame: 1 year
Study treatment completion rate and the causes of any missed treatments
Time frame: Week 8
De-escalation of adjuvant radiotherapy.
Time frame: Week 8
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Cutaneous Squamous Cell Carcinoma
RecruitingPhase 2
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma
RecruitingPhase 3
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma
RecruitingPhase 2
Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System
Locally Recurrent Skin Squamous Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma
RecruitingPhase 3
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
Head and Neck Squamous Cell Carcinoma, Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
Active, not recruitingPhase 2/3
Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Ines Da Silva principal investigator
Melanoma Instiute Australia
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination in people with Cutaneous Squamous Cell Carcinoma, run by Melanoma Institute Australia at 1 site in Australia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 19 inclusion and 43 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 8 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Australia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Monica Osorio (+61 2 9911 7296, monica.osorio@melanoma.org.au), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pathological complete response rate (time frame: Week 6). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jul 2026.